|
|
| (3 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | | __NOTOC__ |
| ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ramipril|{{fontcolor|#6C7B8B|Ramipril}}]]'''''
| | {{CMG}}; {{AE}} {{AZ}}, {{AM}} |
| |-
| | |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ALTACE<sup>®</sup> FDA Package Insert
| | '''''For patient information about Ramipril, click [[Ramipril (patient information)|here]].''''' |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril indications and usage|Indications and Usage]]
| | ===Ramipril=== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril dosage and administration|Dosage and Administration]]
| | * [[Ramipril tablet]] |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril dosage forms and strengths|Dosage Forms and Strengths]]
| | ==Overview== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril contraindications|Contraindications]]
| | '''Ramipril''' tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of [[hypertension]], [[heart failure]], left ventricular dysfunction after [[myocardial infarction]], [[diabetic nephropathy]]. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. [[hypotension]], [[rash]], [[hyperkalemia]], disorder of taste, [[cough]]. |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril warnings and precautions|Warnings and Precautions]]
| | ==Category== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril adverse reactions|Adverse Reactions]]
| | Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril drug interactions|Drug Interactions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril use in specific populations|Use in Specific Populations]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril overdosage|Overdosage]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril description|Description]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril clinical pharmacology|Clinical Pharmacology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril nonclinical toxicology|Nonclinical Toxicology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril clinical studies|Clinical Studies]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril how supplied storage and handling|How Supplied/Storage and Handling]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril patient counseling information|Patient Counseling Information]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ramipril labels and packages|Labels and Packages]]
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Ramipril
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
| |
| |-
| |
| |}
| |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
For patient information about Ramipril, click here.
Ramipril
Overview
Ramipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors.